



transpara®

Powered by FusionAI™



Fusion AI™

The advance in deep
learning radiologists have
been waiting for

More powerful and more intelligent

Introducing FusionAI™, this new platform sets the standard for **Breast AI supported by clinical evidence worldwide.**

A **fusion of knowledge**: breast pathology, clinical imaging, X-ray physics and the latest deep learning techniques, uniquely combined by the scientists at ScreenPoint Medical in collaboration with our clinical partners.

FOR 2D AND 3D MAMMOGRAPHY

Up to **28%**
More accurate¹
Catches **more**
cancers and earlier

Up to **35%**
Of exams with
interval cancers
found earlier² -
Addresses COVID-19
reporting delays

Up to **70%**
Of exams can
confidently be
labelled as normal³ -
Read faster

MATCHES CLINICAL PERFORMANCE OF BREAST RADIOLOGISTS⁴
FOR PEACE OF MIND

Transpara® Powered by FusionAI™ takes deep learning artificial intelligence for 2D and 3D mammography to a new level, opening up new possibilities:

- ▶ For decision support
- ▶ For help with double reading
- ▶ For workload reduction
- ▶ For personalized screening

With FusionAI™, we bring a combination of unique new features to the market. This gives the user a wider range of options to implement evidence based breast AI.

Transpara powered
by FusionAI

2D MAMMOGRAPHY



3D MAMMOGRAPHY



COMBO EXAMS



LATEST 2D AND 3D
MAMMOGRAPHY UNIT
COMPATIBILITY



ENHANCED INTEGRATION
& WORKFLOW



Transpara – the **clinically proven** decision support system



To date, **Transpara** is installed in clinics in over **20 countries**



Over **1 million** mammograms processed with **Transpara**



Trained on over **1 million** images from over **10 countries**



Peer review **published** scientific evidence



Supporting over 35 ongoing international **clinical studies**



True **multivendor** compatibility

FDA cleared and **CE marked** for **2D** and **3D** mammography

www.screenpoint-medical.com

1. Based on relative improvement vs 1.6.0 last year
2. Lång, K., Hofvind, S., Rodríguez-Ruiz, A. et al. Can artificial intelligence reduce the interval cancer rate in mammography screening?. Eur Radiol (2021). <https://doi.org/10.1007/s00330-021-07686-3>, A. Wanders, W. J. Mees, N. Janssen, A. Rodríguez-Ruiz, I. Sechopoulos, N. Karssemeijer, C. J. van Rooden, R. M. Mann. The Potential of AI for Improving Early Detection in Breast Cancer Screening to Reduce Interval Cancer Rates. Presented at RSNA 2020, publication pending
3. S. Romero Martín, J. Luis Raya Povedano, E. Elías Cabot, A. Gubern-Merida, A. Rodríguez-Ruiz, M. Álvarez Benito. Using autonomous AI to reduce the workload of breast cancer screening with breast tomosynthesis: a retrospective validation. Presented at RSNA 2020, publication pending
4. A. Rodríguez-Ruiz, E. Krupinski, J. Mordang, K. Schilling, S. Heywang-Kobrunner, I. Sechopoulos, R. Mann. Detection of breast cancer using mammography: Impact of an Artificial Intelligence support system. Radiology 2019;290 (2), 305-314, FDA approval number K193229.

Transpara 1.7.0 is CE marked. Transpara 1.6.0 is CE marked and FDA cleared. Some features may not be available in all countries, please check with your local representative.

SPM-SMR-001-057 1.6

© 2021 ScreenPoint Medical BV. Transpara® is a registered trademark of ScreenPoint Medical BV. Views and opinions expressed herein by third parties are theirs alone and do not necessarily reflect those of ScreenPoint Medical. This information is intended for medical professionals and is not intended as a product solicitation or promotion where such activities are prohibited. Because ScreenPoint Medical materials are distributed through websites, eBroadcasts and tradeshow, it is not always possible to control where such materials appear. For specific information on what products and features are available in a particular country, please contact your local representative or write to info@screenpointmed.com

ScreenPoint Medical, Toernooiveld 300, 6525 EC Nijmegen, The Netherlands | Tel: +31 242020020

SCREENPOINT
Medical